



VOLUME EIGHTY FIVE

# ADVANCES IN PHARMACOLOGY

## Drug-induced Liver Injury

Edited by

**ANUP RAMACHANDRAN**

*Department of Pharmacology, Toxicology, and  
Therapeutics, University of Kansas Medical Center,  
Kansas City, KS, United States*

**HARTMUT JAESCHKE**

*Department of Pharmacology, Toxicology, and  
Therapeutics, University of Kansas Medical Center,  
Kansas City, KS, United States*

Serial Editor

**S.J. ENNA**

*University of Kansas Medical Center, Kansas City,  
KS, United States*

Managing Editor

**LYNN LeCOUNT**

*University of Kansas Medical Center,  
School of Medicine, Kansas City, KS, United States*



**ACADEMIC PRESS**

An imprint of Elsevier

# Contents

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xiii</i>
<b>1. Primary hepatocytes and their cultures for the testing of drug-induced liver injury</b>	<b>1</b>
Vânia Vilas-Boas, Axelle Cooreman, Eva Gijbels, Raf Van Campenhout, Emma Gustafson, Steven Ballet, Pieter Annaert, Bruno Cogliati, and Mathieu Vinken	
1. Introduction	2
2. Hepatic architecture as the benchmark for liver-based <i>in vitro</i> modeling	3
3. Induction of dedifferentiation during primary hepatocyte isolation	6
4. Counteracting dedifferentiation during primary hepatocyte cultivation	8
5. Testing of drug-induced cholestatic liver injury in primary hepatocyte cultures	16
6. Conclusion	20
Acknowledgments	21
Conflict of interest	22
References	22
<b>2. Cell death in drug-induced liver injury</b>	<b>31</b>
Andrea Iorga and Lily Dara	
1. Introduction	34
2. Modes of cell death	35
3. Conclusions	60
Acknowledgment	61
Conflict of interest	61
References	61
<b>3. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease</b>	<b>75</b>
Julien Allard, Dounia Le Guillou, Karima Begriche, and Bernard Fromenty	
1. Introduction	76
2. Pathophysiology of NAFLD	77
3. Experimental models of NAFLD	79

4. Drug-induced hepatotoxicity in obesity and NAFLD	80
5. Conclusion	96
Acknowledgments	97
Conflict of interest	98
References	98
<b>4. Role and mechanisms of autophagy in alcohol-induced liver injury</b>	<b>109</b>
Xiaojuan Chao and Wen-Xing Ding	
1. Introduction	111
2. Alcohol metabolism	111
3. Autophagy	112
4. Autophagy in ALD mouse models	115
5. Potential therapeutic approaches to treat ALD by modulating autophagy	118
6. Conclusion	123
Acknowledgments	125
Conflict of interest	125
References	125
Further reading	131
<b>5. Mechanisms of idiosyncratic drug-induced liver injury</b>	<b>133</b>
Jack Uetrecht	
1. Introduction	135
2. Involvement of reactive metabolites in the mechanism of IDILI	138
3. Immune system involvement in IDILI	139
4. Other proposed mechanisms of IDILI	143
5. Animal models that can be used for mechanistic studies of IDILI	150
6. Implications for prevention and treatment	152
7. Conclusion	156
Acknowledgment	156
Conflict of interest	156
References	156
<b>6. Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment, and regulatory implications</b>	<b>165</b>
Paul B. Watkins	
1. Introduction	166
2. Clinical phenotypes of IDILI	167
3. Immune phenotypes	171

4. Rating severity of IDILI	173
5. Outcome of an IDILI event	174
6. Death or transplant	176
7. Chronic DILI	176
8. Predicting IDILI course	177
9. Diagnosing IDILI	179
10. Detecting IDILI potential of new drugs in clinical trials	181
11. The FDA approach to assess liver safety in clinical trials	183
12. Causality assessment in clinical trials	186
13. Conclusion	189
References	189
<b>7. Acetaminophen hepatotoxicity: A mitochondrial perspective</b>	<b>195</b>
Anup Ramachandran and Hartmut Jaeschke	
1. Introduction	196
2. Mitochondria in APAP overdose	197
3. Mitochondrial protein adducts in APAP hepatotoxicity	198
4. APAP induced mitochondrial oxidative and nitrosative stress	200
5. Consequences of mitochondrial oxidative/nitrosative stress in the cytosol	204
6. Mitochondrial amplification of injury	206
7. The end game: Mitochondrial permeability transition and subsequent cellular necrosis	207
8. Mitochondria in adaptation and recovery after APAP overdose	209
9. Role of mitochondria-derived damage-associated molecular patterns in injury and recovery	210
10. Relevance of APAP-induced mitochondrial dysfunction to humans	211
11. Conclusion	212
Acknowledgments	212
Conflict of interest statement	213
References	213
<b>8. Biomarkers of drug-induced liver injury</b>	<b>221</b>
Mitchell R. McGill and Hartmut Jaeschke	
1. Introduction	222
2. The problem of low prevalence in DILI biomarker development	223
3. Biomarkers of DILI diagnosis	226
4. Biomarkers of DILI prediction	227
5. Biomarkers of DILI prognosis	228

6. Mechanistic biomarkers	231
7. Conclusion	233
Acknowledgments	233
Conflict of interest	233
References	234
<b>9. Mechanisms and biomarkers of liver regeneration after drug-induced liver injury</b>	<b>241</b>
Melissa M. Clemens, Mitchell R. McGill, and Udayan Apte	
1. Introduction	242
2. Etiology and prognosis of acute liver injury	243
3. Major differences between hepatectomy and hepatotoxicity	244
4. Regeneration after drug-induced liver injury	245
5. Biomarkers of liver regeneration	253
6. Conclusion	254
Conflict of interest statement	255
Acknowledgments	255
References	255
Further reading	262
<b>10. Evaluation and treatment of acetaminophen toxicity</b>	<b>263</b>
Erik S. Fisher and Steven C. Curry	
1. Introduction	264
2. Acute acetaminophen ingestions	264
3. Chronic APAP oral ingestions	270
4. Conclusion	270
Conflict of interest	271
References	271